AI MARKET SCANNING

Annovis Bio, Inc.

🏛️ NYSE 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP +1.44%
MAX GAP RECORD +16.47%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $ANVS
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Aug 14, 2026 Earnings Release 2026-08-14 (BEFORE OPEN)
+2.23%
May 15, 2026 Earnings Release 2026-05-15 (BEFORE OPEN)
-4.69%
Mar 13, 2026 Earnings Release 2026-03-13 (AFTER CLOSE)
+0.79%
Nov 12, 2025 Earnings Release 2025-11-12 (BEFORE OPEN)
+2.84%
Aug 12, 2025 Earnings Release 2025-08-12 (AFTER CLOSE)
-3.61%
May 13, 2025 Earnings Release 2025-05-13 (AFTER CLOSE)
+16.47%
Mar 21, 2025 Earnings Release 2025-03-21 (AFTER CLOSE)
-0.57%
Nov 08, 2024 Earnings Release 2024-11-08 (AFTER CLOSE)
-1.96%

VOLATILITY & GAP BIAS

AVG GAP MOVE 5.1%
Bullish Gaps (7)
Bearish Gaps (4)
Neutral / Flat (2)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $ANVS

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗